# A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

> **NCT07060807** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1000 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **BIOLOGICAL:** Patritumab deruxtecan
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Capecitabine
- **DRUG:** Liposomal doxorubicin
- **BIOLOGICAL:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT07060807
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-21
- **Primary completion:** 2033-07-14
- **Final completion:** 2033-07-14
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07060807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07060807, "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07060807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*